Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma Monrovia, Calif. – February 11, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, has initiated a Phase I clinical trial with its lead product candidate XmAb™2513 in patients with Hodgkin lymphoma (HL) and
Human Genome Sciences And Xencor Announce Antibody Collaboration ROCKVILLE, Maryland and MONROVIA, California – February 7, 2008 – Human Genome Sciences, Inc. (Nasdaq: HGSI) and Xencor, Inc. today announced a collaboration agreement under which Xencor will apply its proprietary XmAb™ humanization
Xencor Receives Patent for its Proprietary Antibody Fc Optimization Technology Monrovia, Calif. – January 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it received a patent from the United States Patent and Trademark Office (US 7,317,091 B1)
Xencor Data from Pre-clinical XmAb™ Antibody Studies Presented at American Society of Hematology Meeting Monrovia, Calif. – December 10, 2007 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today the presentation of results from pre-clinical studies evaluating two
Xencor Presents Findings on New Aspect of its Fc Technology Targeting Autoimmune Disease Monrovia, Calif. — December 7, 2007 — Xencor, Inc., a company developing protein and antibody therapeutics, presented findings at IBC Life Sciences’ 17th Annual Antibody Engineering Conference demonstrating the
Xencor Expands Series E Financing to $60 Million MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, a company developing protein and antibody therapeutics, today announced that it raised an additional $15 million in an extension of its Series E financing, bringing the total raised in this round to $60
Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, a company developing protein and antibody therapeutics, today announced the appointment of Jeffrey D. Bloss, M.D., F.A.C.O.G., as chief medical officer. Dr.
Xencor Selects Antibody Development Candidates MONROVIA, Calif.—(BUSINESS WIRE)—Xencor, Inc., a leader in antibody optimization, has selected two humanized monoclonal antibody candidates, XmAb™ 5574 and XmAb™ 5483, for IND-enabling pre-clinical development for the treatment of B-cell malignancies
Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease MONROVIA, Calif.–(BUSINESS WIRE)–Jul 23, 2007 – A first-in-class protein therapeutic drug candidate has been shown to selectively inhibit its therapeutic target, according to
Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement Monrovia, CA – February 13, 2007. Xencor, Inc., a protein and antibody therapeutics development company, today announced a collaboration with Boehringer Ingelheim to optimize therapeutic monoclonal